Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers
Year: 2019
Type: article
Study design: Observational Study
Abstract: Colorectal cancer (CRC) with CpG island methylator phenotype (CIMP) is recognized as a subgroup of CRC that shows association with particular genetic defects and patient outcomes. We analyzed CIMP status of 229 individuals with CRC using an eight-marker panel (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); CIMP-(+) tumors were defined as having ≥ 5 methylated markers. Patients were divided into individuals who developed a "unique" CRC, which were subclassified into early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and patients with multiple primary CRCs subclassified into synchronous CRC (SCRC) and metachronous CRC (MCRC). We found 9 (15.2%) CIMP-(+) EOCRC patients related with the proximal colon (p = 0.008), and 19 (26.8%) CIMP-(+) LOCRC patients associated with tumor differentiation (p = 0.045), MSI status (p = 0.021) and BRAF mutation (p = 0.001). Thirty-five (64.8%) SCRC patients had at least one CIMP-(+) tumor and 20 (44.4%) MCRC patients presented their first tumor as CIMP-(+). Thirty-nine (72.2%) SCRC patients showed concordant CIMP status in their simultaneous tumors. The differences in CIMP-(+) frequency between groups may reflect the importance of taking into account several criteria for the development of multiple primary neoplasms. Additionally, the concordance between synchronous tumors suggests CIMP status is generally maintained in SCRC patients.
Source: Scientific Reports
Institutions: Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Hospital General Universitario Gregorio Marañón, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Spanish National Cancer Research Centre, Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases, City of Hope, Beckman Research Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,790
Awards: G2224762734, G251590960, G312429407, G3173870227, Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer, G3411000325, G3695502894, G4144402113, G4300560175, G6681643532, G7049232908, Next Generation Sequencing-Based Approaches for the Development of Epigenetic Biomarkers for Predicting Therapeutic Outcome in Patients With Colorectal Cancer, Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data, Methylation Biomarker Development for Noninvasive Detection of Colorectal Cancer, G9000004785, G9000016337, G9000169660, G9000182627, G9000208368, G9000226584
OpenAlex ID: W2963901948